"Why do you think this team will be able to get government money for an ACTIV clinical trial after being unable/unwilling to get BARDA money for Brilacidin as a novel antibiotic?"
After working in the other part of the agency BARDA is housed in, and, after you subtract more than a bit for incompetence and probable fraudulent perspectives, a failure at BARDA may not be a total dead issue. But Leo coming back, successfully, is just not something I see him doing. And he'd have to be a better salesman than he was before (If he even made a pitch, we'll never know). In honesty, I have not kept up with the new BARDA leadership, we can hope they will relook at Brilacidin, and so many other things of merit they overlooked, and they could; but usually only if the CEO makes a new pitch based on BARDA's past and huge failures to conduct its mission with integrity and competence. Is Leo slick and competent enough? He is at fleecing the longs, but not sure of much else.
News 
Market Data 
Discover 
